Cochlear Ord Adr - CHEOY STOCK NEWS

Cochlear Limited (ASX: COH) has received FDA approval for its Cochlear Nucleus Implants to treat unilateral hearing loss (UHL) and single-sided deafness (SSD). This approval expands treatment options for approximately 60,000 people in the U.S. who acquire SSD annually. Existing implants were only approved for bilateral sensorineural hearing loss. The company aims to raise awareness about effective treatments and offers various implantable hearing solutions to improve the quality of life for those affected.

Cochlear Limited has received FDA approval and clearance for its Cochlear Remote Assist solution, applicable to the Nucleus and Baha Systems, marking a significant advancement in remote hearing care. This first-of-its-kind solution allows clinicians to connect with patients through a live video session, enabling remote programming and adjustments of hearing devices. The commercial launch is anticipated in spring 2022, enhancing Cochlear's existing remote care offerings and providing more flexible options for patient management. The company aims for further approvals in Canada by early 2022.

Sensorion and Cochlear Limited have initiated a pilot study for SENS-401 (Arazasetron) aimed at enhancing hearing outcomes after cochlear implantation. The study is fully funded under an existing agreement and will assess the pharmacokinetics of SENS-401 and its therapeutic effects. Preliminary preclinical studies showed SENS-401 preserved residual hearing significantly compared to placebo. The regulatory submission for the study design is expected in the latter half of 2021. This collaboration aims to validate the efficacy of combining cochlear implants with pharmacological therapies.

Lou Ferrigno, known for his role in 'The Incredible Hulk', recently received a cochlear implant to address his long-standing hearing loss. This month celebrates Better Hearing and Speech Month, with Ferrigno sharing his positive experience post-surgery. After years of ineffective hearing aids, his cochlear implant, the Cochlear Nucleus® Profile™ Plus Implant, has significantly improved his hearing clarity. Research indicates that cochlear implants are the FDA-approved solution for profound hearing loss, yet only 5% of those who could benefit have them.

Cochlear Limited has launched a new mobile app, Cochlear CoPilot, aimed at enhancing the listening and communication skills of adults with cochlear implants. Available for free on the App Store in the US and Canada, this self-guided digital tool includes expert articles and interactive skill builders. Research indicates that while cochlear implants provide access to sound, additional rehabilitation through knowledge and skill training is necessary for optimal outcomes. The app is designed to make rehabilitation more accessible and effective, supporting users in their daily communication challenges.

Cochlear Limited (ASX: COH) has received FDA clearance for the new Baha 6 Max Sound Processor, designed to enhance hearing for individuals with single-sided deafness and other hearing loss types. This device features a fitting range up to 55 dB, making it the smallest and most powerful bone conduction processor available. Key improvements include direct streaming from Apple and Android devices, enhanced noise reduction, a frequency range up to 9.7 kHz, and a 50% longer battery life. The device aims to provide a clearer, richer sound experience while being user-friendly for both adults and children.

Cochlear welcomes the WHO's first World Report on Hearing, launched on March 3, 2021, which calls for prioritizing hearing health globally. The report highlights that 1.5 billion people experience some degree of hearing loss, with around 60 million facing severe to complete loss. It emphasizes the effectiveness and cost-effectiveness of cochlear implants and urges member states to integrate hearing care into primary health systems. Cochlear's CEO, Dig Howitt, stresses the need for urgent action to tackle the rising prevalence of hearing loss, supported by prominent advocates like Malala Yousafzai.

Cochlear Limited (ASX: COH) announced the winners of the 2021 Graeme Clark and Anders Tjellström Scholarships, recognizing eight exemplary Cochlear™ Nucleus® Implant, Baha® System, and Osia® System recipients from the U.S. and Canada. Each winner will receive $2,000 per year for up to four years, totaling $64,000 in scholarships for this year alone. Since 2002, the company has awarded $824,000 to 112 students. The scholarships aim to support Cochlear recipients in achieving their educational and career goals while promoting leadership in the hearing loss community.

Cochlear Limited (ASX: COH) launched the Hearing 20/20 campaign during Audiology Awareness Month to promote a common metric for normal hearing: 20 decibels in each ear. Supported by ten partners, this initiative aims to emphasize the significance of hearing health, especially for adults aged 55 and older. The campaign highlights that the third most common chronic condition, hearing loss, impacts many, yet only 9% of consumers know its definition. Cochlear encourages annual hearing tests and discussions regarding hearing health with primary care providers.